- Home
- HURA vs CLNN Comparison
HURA vs CLNN Comparison
Compare HURA & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | CLNN |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 120.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HURA | CLNN |
|---|---|---|
| Price | $0.74 | $5.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 420.4K | 96.2K |
| Earning Date | 02-14-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $2.28 |
| 52 Week High | $5.27 | $13.50 |
Technical Indicators
Market Signals| Indicator | HURA | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 36.44 |
| Support Level | $0.70 | $4.50 |
| Resistance Level | $0.81 | $6.68 |
| Average True Range (ATR) | 0.07 | 0.61 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 36.67 | 31.06 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.